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Abstract The purpose of this report is to describe the
overall safety profile of both short- and longer-term
duloxetine treatment of fibromyalgia. Data from four
double-blind, randomized, placebo-controlled studies (two
with 6-month open-label extension phases) and a 1-year,
open-label safety study were included. Safety measures
included treatment-emergent adverse events (TEAEs),
adverse events leading to discontinuation, serious adverse
events (SAEs), clinical laboratory tests, vital signs, and
electrocardiograms. The most common TEAEs for short-
term treatment with duloxetine were nausea (29.3%),
headache (20.0%), dry mouth (18.2%), insomnia (14.5%),
fatigue (13.5%), constipation (14.5%), diarrhea (11.6%),
and dizziness (11.0%; all p<0.05 vs. placebo). Most
TEAEs emerged early and were mild to moderate in
severity. The profile of adverse events in patients enrolled
at least 6 months, and for patients in the 1-year study, was
similar to that found in the short-term treatment studies,
with no new adverse events emerging at a notable rate.
About 20% of patients discontinued due to adverse events
in the short-term treatment studies and in the 1-year study.
SAEs were uncommon, and none occurred at a significantly
higher frequency for duloxetine compared with placebo.
Mean changes in vital signs and weight were small. Rates
of treatment-emergent potentially clinically significant
(PCS) vital sign, laboratory, and electrocardiogram meas-
ures were low, with only PCS rates of alanine aminotrans-
ferase being significantly higher for duloxetine compared
with placebo in the placebo-controlled treatment studies. In
the 1-year study, four patients (1.1%) had suicide-related
behavior. The data provided here summarize short- and
long-term safety from five clinical studies in patients
treated with duloxetine for fibromyalgia. In addition,
postmarketing surveillance continues for adverse events
reported with duloxetine in fibromyalgia, as in other
indications.
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Introduction
Fibromyalgia (FM) is a chronic musculoskeletal disorder
characterized by widespread pain. The overall prevalence of
FM is about 2%, although rates are higher for women
compared with men [1, 2]. FM is associated with substantial
functional disability, work impairments, fatigue, sleep
disturbances, and high rates of health care utilization [3–6].
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four quadrants along with axial skeletal pain for at least
3 months and tenderness must be elicited on physical exam
at 11 or more of 18 specified tender point sites [7]. The pain
and tenderness in FM is thought by some to be due to
central sensitization [8]. Consistent with this hypothesis,
patients with FM have qualitatively altered nociception
compared with pain-free patients [9–11]. Both serotonin
and norepinephrine are believed to play a role in the
modulation of pain via the descending inhibitory pain
pathways in the brain and spinal cord [12, 13]. Dysfunction
in pain perception is one of the proposed etiological factors
in FM, although the exact pathophysiological mechanism
of FM is unknown [14–17].
Duloxetine has shown efficacy in placebo-controlled
trials in both psychiatric and pain disorders, including
major depressive disorder (MDD), generalized anxiety
disorder (GAD), diabetic peripheral neuropathic pain
(DPNP), and FM [18–32]. The safety of duloxetine has
been reported in individual trials and some pooled study
analyses [33–36] in patients with MDD, GAD, DPNP, FM,
and lower urinary tract disorders. While the safety and
tolerability of duloxetine for the treatment of FM have been
previously published for the individual clinical trials [18–
22], a pooled analysis may offer a better overview of this
topic than what individual study results can provide.
Patients with fibromyalgia are often perceived as having
poor tolerance for medications, perhaps related to overall
heightened central sensitivity. The purpose of the current
article is to present a comprehensive profile of the safety
and tolerability of duloxetine during both short- (up to 6
months) and long-term (up to 60 weeks) use in patients
with fibromyalgia.
Materials and methods
Study design
To evaluate the safety of duloxetine in the treatment of FM,
data were drawn from five studies. Studies 1 to 4 were
double-blind, randomized, placebo-controlled, multicenter
efficacy studies. Study 5 was a 1-year open-label safety
study without a placebo control.
In study 1, patients were randomly assigned to fixed
dosages of duloxetine 60 mg BID (twice per day; n=104)
or placebo (n=103). In study 2, patients were randomly
assigned to fixed dosages of duloxetine 60 mg QD (once
daily; n=118), duloxetine 60 mg BID (n=116), or placebo
(n=120). In study 3, patients were randomly assigned to
fixed dosages of duloxetine 20 mg QD (n=79), duloxetine
60 mg QD (n=150), duloxetine 120 mg QD (n=147), or
placebo (n=144). After 15 weeks, patients in the 20 mg
duloxetine group were increased to 60 mg QD and
continued on that dose for 13 more weeks. Patients
receiving 60 mg duloxetine, 120 mg duloxetine, or placebo
during the first 15 weeks were also continued on their
respective treatments for 13 more weeks, for a total of
28 weeks of placebo-controlled treatment. Patients who
completed the 28-week course of treatment in study 3 were
eligible to participate in a further 28-week extension phase
in which all patients received 120 mg QD of duloxetine. In
study 4, patients were randomly assigned to 23 weeks of
duloxetine treatment (8 weeks at 60 mg QD followed by
15 weeks of duloxetine continuing at 60 mg QD or
increasing to 120 mg QD depending on clinical response
and tolerability; n=162) or placebo (n=168). All patients
who completed the initial therapy phase in study 4 were
eligible to enter a 29-week double-blind extension phase at
either 60 or 120 mg QD depending on dose at the end of
the short-term therapy phase. Study 5 had an open-label
phase of 8 weeks of duloxetine 60 mg QD treatment
(n=350), followed by a 52-week double-blind phase in
which patients were randomly assigned in a 1:2 ratio to
continue at 60 mg QD (n=104) or 120 mg QD (n=203) of
duloxetine, respectively. In all studies, patients assigned to
doses at or above 60 mg/day were titrated briefly using
doses of 20 or 30 mg/day. At study completion or
discontinuation, a blinded taper phase lasting 1 or 2 weeks
was implemented in all studies to prevent abrupt discon-
tinuation of duloxetine treatment.
All patients provided written informed consent, and all
study protocols were approved by the ethical review board
at each investigative site. Further details about the methods
and procedure of studies 1 through 5 can be found in
published reports [18–22].
Patients
Patients were ≥18 years of age, male or female outpatients
(only female for study 2), with or without MDD. All
patients met the criteria for FM as defined by the American
College of Rheumatology. Patients in all studies were also
required to have a score of ≥4 on either the pain intensity
item of the Fibromyalgia Impact Questionnaire [37] (study
1) or the average pain item of the Brief Pain Inventory [38]
(studies 2–5). Patients were excluded from each study if
they had any current primary psychiatric diagnosis other
than MDD, including a current or past year diagnosis of
dysthymia; had a previous diagnosis of psychosis, bipolar
disorder, or schizoaffective disorder; had any anxiety
disorder as a primary diagnosis within the past year; had a
history of substance abuse or dependence within the past
year (excluding nicotine and caffeine); or had a positive
urine drug screen for any substances of abuse. Patients with
an abnormal C-reactive protein level that is indicative of an
1036 Clin Rheumatol (2009) 28:1035–1044autoimmune disease, an antinuclear antibody with a
dilution of >1:320, or a rheumatoid factor of ≥15 IU/mL
were excluded. Patients who were pregnant or breastfeed-
ing, were a serious suicidal risk, or had a serious medical
illness were also excluded. At baseline and over the course
of the studies, concomitant medications with primarily
central nervous system activity were not permitted.
Safety measures
All studies evaluated safety on the basis of discontinuation
rates, treatment-emergent adverse events (TEAEs); serious
adverse events (SAEs); laboratory test results, including
blood chemistry and hematology; vital signs; weight; and
electrocardiograms (ECGs). TEAEs were assessed at each
visit by recording patient responses to a general question
such as, “How have you been feeling?” TEAEs were coded
to Medical Dictionary for Regulatory Activities preferred
terms by blinded clinical personnel. An adverse event was
considered treatment emergent if it was either new or
existing but worsened after initiation of study medication.
The severity of each adverse event as mild, moderate, or
severe was also recorded. Discontinuation-emergent ad-
verse events were assessed during the 1–2-week tapered
discontinuation phases. Suicide-related events were identi-
fied by a text string search of adverse events and
investigator comments to allow for evaluation of incidences
of suicidal ideation or suicidal behavior.
Vital signs consisting of supine and standing blood
pressure (BP) and pulse were recorded at each visit.
Laboratory tests were performed at regular visits through
the treatment periods; ECGs were conducted at the final
visit of the short-term phase for study 1, weeks 15 and 28
for study 3, and weeks 13 and 27 for study 4 (ECGs not
conducted postbaseline in studies 2 and 5). The criteria for
potentially clinically significant (PCS) ECG values were as
follows: PR interval: low—any value <20, high—any value
>200; QRS interval: low—any value <50, high—any value
>120; QTcF interval: abnormal—increase ≥30 from base-
line and postbaseline value ≥450 ms for males, ≥470 ms for
females. PCS values for vital signs and weight are given in
the legend of Table 6.
Statistical analyses
To assess duloxetine safety during short-term treatment,
data from the 3- and 6-month placebo-controlled phases of
studies 1 to 4 were pooled. Longer-term safety and
tolerability of duloxetine was examined in two ways: (1)
all patients that enrolled in the 60-week study (study 5) and
(2) all patients continuing into the 6-month extension
phases of studies 3 and 4 and all patients from study 5
maintaining enrollment for at least 6 months (to assess
safety in patients with a minimum of 6 months of drug
exposure). All analyses were intent-to-treat analyses, unless
otherwise specified, using all participants by the groups to
which they were assigned by random allocation. Statistical
significance was indicated when p≤0.05. No adjustments
were made for multiplicity.
For the placebo-controlled data, comparisons of dulox-
etine and placebo on rates of TEAEs, reasons for
discontinuation, and rates of PCS values for vital signs,
weight, laboratory test results, and ECGs were performed
using the Cochran–Mantel–Haenszel general association
test controlling for study. For vital signs, weight, and
ECGs, treatment group differences in mean change from
baseline to endpoint (last observation on treatment) were
analyzed using an analysis of variance model containing
terms for treatment group and study. Time-to-onset and
time-to-resolution of adverse events were examined using
the product limit approach, and tests for significance
between treatment groups were based on the log-rank test.
Suicidal ideation and behavior were compared between the
duloxetine and placebo groups based on exposure-adjusted
Mantel–Haenszel incidence rates derived from the above-
mentioned text string search.
Results
Patient characteristics
The study population of patients (n=1,411) receiving short-
term treatment was primarily (94.8%) women. The mean
age was 50.2 (SD=11.0) years, and most (87.5%) of the
participants were of Caucasian origin. There were no
statistically significant differences between the duloxetine-
and placebo-treated patients on any of the baseline
characteristics (Table 1). Duloxetine-treated patients who
had at least 6 months of study participation (n=721) and
the sample of 350 patients who participated in the longer-
term (1 year) study of duloxetine had similar baseline
characteristics, although the minority representation was
higher in the 1-year study.
Drug exposure
For the short-term placebo-controlled studies, a total of 876
patients were exposed to duloxetine for a mean of 110 days,
and 535 patients were exposed to placebo for a mean of
105 days. Of the duloxetine-treated patients in these
studies, 46.7% were exposed to drug for at least 3 months
(compared with 42.1% for placebo). For the sample
enrolled in studies for at least 6 months, 91.3% (of 721
patients) were exposed to duloxetine for 6 months or more,
and 61.9% were exposed for 1 year or more with an
Clin Rheumatol (2009) 28:1035–1044 1037average exposure period of 327 days. In the longer-term
study, 350 patients were exposed to duloxetine for a mean
of 298 days, with 69.1% receiving at least 6 months of
exposure and 58.7% receiving at least 1 year of exposure.
Discontinuations
Overall, 41.4% of the duloxetine-treated patients and
42.2% of the placebo-treated patients discontinued short-
term treatment (Table 2). Adverse events were the cause
of early discontinuation for 19.5% of those in the
duloxetine group and 11.8% in the placebo group during
short-term treatment (p<0.001). Lack of efficacy was a
reason for discontinuation significantly (p<0.001) less
often for duloxetine- compared with placebo-treated
patients (7.0% and 13.5%, respectively) in the short-term
studies. There were no other significant differences in
other reasons for discontinuation between the duloxetine
and placebo groups in the short-term studies. Among
those who were enrolled for at least 6 months, 31.9%
discontinued treatment, with adverse events the most
common reason (Table 2). In the 1-year study, 44.9%
discontinued early, with adverse events a reason for
discontinuation for 21.1% of patients (Table 2).
Table 2 Reasons for study discontinuation
Primary reason for
discontinuation
3–6-Month studies ≥6-Month exposure 1-Year study
Placebo (N=535)
frequency (%)
Duloxetine (N=876)
frequency (%)
p
a (duloxetine
vs. placebo)
Duloxetine (N=721)
frequency (%)
Duloxetine (N=350)
frequency (%)
DC due to any reason 226 (42.2) 363 (41.4) 0.44 230 (31.9) 157 (44.9)
Adverse event 63 (11.8) 171 (19.5) <0.001 90 (12.5) 74 (21.1)
Lack of efficacy 72 (13.5) 61 (7.0) <0.001 24 (3.3) 29 (8.3)
Subject decision 44 (8.2) 59 (6.7) 0.16 85 (11.8) 26 (7.4)
Lost to follow-up 31 (5.8) 38 (4.3) 0.06 6 (0.8) 9 (2.6)
Protocol violation 14 (2.6) 22 (2.5) 0.99 13 (1.8) 9 (2.6)
Physician decision 2 (0.4) 9 (1.0) 0.24 10 (1.4) 8 (2.3)
Sponsor decision 0 (0) 2 (0.2) 0.24 2 (0.3) 2 (0.6)
Entry exclusion criteria 0 (0) 1 (0.1) 0.54 ––
aFrom Cochran–Mantel–Haenszel test for general association controlling for study
DC discontinuation
Table 1 Patient characteristics
Variable 3–6-Month studies ≥6-Month exposure 1-Year study
Placebo (N=535) Duloxetine (N=876) p
a (duloxetine vs. placebo) Duloxetine (N=721) Duloxetine (N=350)
Ethnicity, n (%) 0.916
African 13 (2.4%) 20 (2.3%) 5 (0.7) 3 (0.9)
Caucasian 463 (86.5%) 771 (88.0%) 560 (77.7) 214 (61.1)
East Asian 3 (0.6%) 3 (0.3%) 33 (4.6) 46 (13.1)
Hispanic 51 (9.5%) 76 (8.7%) 116 (16.1) 82 (23.4)
Nat. Amer. 1 (0.2%) 2 (0.2%) 4 (0.6) 1 (0.3)
Other 3 (0.6%) 2 (0.2%) ––
West Asian 1 (0.2%) 2 (0.2%) 3 (0.4) 4 (1.1)
Age, years
b 49.61 (11.32) 50.62 (10.76) 0.147 50.48 (10.56) 48.97 (11.07)
Gender, n (%) 0.265
Female 509 (95.1%) 829 (94.6%) 692 (96.0) 335 (95.7)
Height (cm)
2 163.14 (7.49) 163.32 (7.78) 0.512 161.76 (7.47) 159.44 (7.09)
Weight (kg)
2 78.15 (18.40) 79.71 (19.46) 0.582 76.84 (18.37) 69.95 (14.74)
aFrequencies were analyzed using Cochran–Mantel–Haenszel test for general association controlling for study; means were analyzed using a type
III sums of squares analysis of variance: model = treatment and study
bMean (SD)
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Most (59.3%) of the TEAEs reported by duloxetine-
treated patients in the short-term studies were described
as mild (21.1%) or moderate (38.2%) in severity. The
most common TEAEs as reported by >10% of patients
during short-term treatment were nausea, headache, dry
mouth, insomnia, fatigue, constipation, diarrhea, and
dizziness in the duloxetine-treated patients (Table 3).
All of these, plus somnolence, hyperhidrosis, and de-
creased appetite, occurred significantly (all p<0.05) and
more frequently in the duloxetine group than the placebo
group. No specific adverse events led to discontinuation
in the duloxetine group at a significantly higher rate than
the placebo group, with the exception of somnolence
(p=0.003; Table 4).
In the short-term studies, the common (>10%) TEAEs
occurred early in treatment and had a relatively rapid
resolution (Table 3). All of the most common (>10%)
TEAEs associated with duloxetine had a significantly (all
p<0.05) earlier onset for duloxetine- compared with
placebo-treated patients. However, the time from onset to
resolution for all of these most common duloxetine-
associated TEAEs was not significantly different between
duloxetine and placebo.
The same TEAEs that were common (>10%) in the short-
term studies were also common among those enrolled for at
least 6 months and in the 1-year study (Table 3). In addition,
somnolence and hyperhidrosis occurred for more than 10%
of patients. In general, the rates of adverse events among
those enrolled for at least 6 months and in the 1-year study
were slightly higher than in the short-term studies, but no
new adverse events emerged with any frequency. In the 1-
year study, rates of discontinuations due to specific adverse
events were similar to the short-term studies (Table 4).
Serious adverse events
A total of 21 (2.4%) duloxetine-treated and 11 (2.1%)
placebo-treated patients reported at least one SAE in the
short-term studies. There were no statistically significant
treatment group differences in the incidence of individual
SAEs. Additionally, there was no pattern of SAEs with
respect to system-organ class. No one SAE occurred at a
frequency greater than others among duloxetine-treated
patients. Among the 721 duloxetine-treated patients en-
rolled for at least 6 months, 42 (5.8%) had an SAE.
Similarly, a total of 19 (5.4%) duloxetine-treated patients
experienced at least one SAE in the 1-year study. No
specific pattern in the incidence of specific SAEs was
Table 3 Treatment-emergent adverse events
3–6-Month studies ≥6-Month
exposure
1-Year
study
Time to
Onset (days)
Time to
Resolution (days)
Event
a PBO
(N=535)
DLX
(N=876)
PBO DLX PBO DLX DLX
(N=721)
DLX
(N=350)
%%p
b (duloxetine
vs. placebo)
Mdn Mdn Mdn Mdn % %
Nausea 11.4 29.3 <0.001 10.5 1.0 9.0 6.0 30.2 40.6
Headache 12.0 20.0 <0.001 14.0 9.0 9.0 8.0 26.1 29.4
Dry mouth 5.2 18.2 <0.001 13.0 4.0 32.0 73.0 22.2 17.1
Insomnia 9.2 14.5 0.003 26.0 8.0 43.0 34.0 16.4 19.7
Fatigue 7.1 13.5 <0.001 26.0 7.0 39.0 54.0 12.2 11.1
Constipation 3.6 14.5 <0.001 16.0 10.0 74.0 47.0 18.3 17.4
Diarrhea 7.9 11.6 0.018 14.0 3.0 5.0 4.0 14.3 12.9
Dizziness 6.7 11.0 0.011 10.5 6.0 7.5 7.5 15.5 18.9
Somnolence 2.8 9.6 <0.001 2.0 3.0 59.0 50.5 11.8 14.0
Hyperhidrosis 1.1 6.8 <0.001 31.5 22.0 33.0 49.0 13.7 11.4
Decreased appetite 0.6 6.5 <0.001 7.0 2.0 68.0 32.0 5.7 4.6
Estimates of median times for the adverse events are based on the first new occurrence after initiation of treatment for the subsample of patients
who experienced each event.
PBO placebo, DLX duloxetine, Mdn median
aEvent list comprises those treatment-emergent adverse events in the 3–6-month studies for which the rate for duloxetine was ≥5.0% and
significantly higher than placebo
bCochran–Mantel–Haenszel test for general association, controlling for study
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of the five studies.
Suicidality
Three cases of suicide ideation (one on duloxetine, two on
placebo; p=0.86) were identified during the short-term,
placebo-controlled studies. An exposure-adjusted analysis
of these rates of suicide ideation also revealed no
significant (p=0.29) difference between duloxetine and
placebo. In the 1-year study, there were four patients
(1.1%) who had suicide-related behavior (three suicidal
ideations and one suicide attempt).
Vital signs and weight
Mean changes from baseline to endpoint of short-term
treatment in the 3–6-month studies for all vital signs were
relatively small for duloxetine (Table 5). With the large
sample sizes, differences between duloxetine and placebo
were statistically significant, with duloxetine evidencing
slight increases in pulse, systolic BP, and diastolic BP, and a
slight decrease in body weight, relative to placebo. For the
sample of patients enrolled for 6 months or more and the 1-
year study, there were similar small mean changes in vital
signs from baseline to endpoint (Table 5).
Rates of treatment-emergent PCS values for vital signs
and weight changes were low in the short-term studies
(Table 6). No significant differences between the duloxetine
and placebo groups were evident for pulse, sitting systolic
BP, sitting diastolic BP, body weight, or the incidence of
sustained elevation in BP (for systolic BP, 1.3% in the
duloxetine group and 1.1% in the placebo group had a
sustained elevation, p=0.74; for diastolic BP, 0.7% of the
duloxetine group and 0.2% of the placebo group had a
sustained elevation, p=0.17).
Within the sample of duloxetine-treated patients who
were enrolled for 6 months or more, treatment-emergent
Table 5 Mean baseline and change (to endpoint) on vital signs and weight
3–6-Month studies ≥6-Month exposure 1-Year study
Placebo
(N=527)
Duloxetine
(N=855)
p
a (duloxetine
vs. placebo)
Duloxetine
(N=721)
Duloxetine
(N=350)
Pulse Baseline 73.3 (9.9) 73.7 (9.7) 74.2 (9.5) 75.2 (8.7)
Change −0.4 (9.5) 1.2 (10.6) 0.003 2.3 (11.0) 1.9 (10.4)
Sitting diastolic BP Baseline 76.7 (9.2) 76.4 (8.9) 77.0 (9.2) 76.9 (9.3)
Change −1.2 (8.9) 1.0 (9.2) <0.001 0.8 (9.5) −0.2 (9.6)
Sitting systolic BP Baseline 122.5 (14.9) 122.3 (15.3) 122.4 (15.8) 120.1 (14.8)
Change −1.6 (13.2) 0.9 (14.7) 0.003 0.2 (13.9) −0.1 (14,4)
Weight (kg) Baseline 77.9 (18.2) 79.9 (19.5) 76.8 (18.4) 69.9 (14.7)
Change 0.3 (2.4) −0.4 (4.2) 0.002 0.6 (5.0) 0.7 (4.3)
aFrom analyses of variance with study and treatment as effects
BP blood pressure
Table 4 Discontinuations due to adverse events
3–6-Month studies 1-Year study
Event
a Placebo (N=535) Duloxetine (N=876) p
b (duloxetine vs. placebo) Duloxetine (N=350)
%% %
Nausea 0.7 1.9 0.074 1.4
Insomnia 0.7 1.1 0.411 2.6
Fatigue 0.2 1.3 0.073 0.6
Diarrhea 0.2 0.8 0.077 1.4
Dizziness 0.6 0.7 0.672 1.4
Somnolence 0 1.5 0.003 0.3
Vomiting 0.2 0.5 0.390 2.0
aEvent list comprises any adverse events that led to discontinuation in >1% of patients in either the 3–6-month studies or the long-term study
bCochran–Mantel–Haenszel test for general association, controlling for study
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individuals; 4.0% had PCS decreases in weight. Rates for
treatment-emergent values for vital signs were very low
(0% to 0.4%). Similar results were evident in the 1-year
study (Table 6).
A total of 2.2% (16 of 721) of patients enrolled for
6 months or more had a sustained elevation in systolic BP;
2.1% (15 of 721) had a sustained elevation in diastolic BP. In
the 1-year study, sustained elevations in systolic BP occurred
for five (1.4%) patients and sustained elevations in diastolic
BP occurred for 10 (2.9%) patients.
Electrocardiogram
There were no significant treatment group differences in the
incidence of PCS values for any ECG parameters in the
3–6-month pooled study data. PCS rates for duloxetine and
placebo were as follows: PR interval (high)—1.1%, 2.3%,
p=0.19; PR interval (low)—3.0%, 1.4%, p=0.09; QRS
(high)—1.3%, 1.2%, p=0.68; QRS interval (low)—0%,
0%; QTcF (abnormal)—0.4%, 0.3%, p=0.79. Mean
changes from baseline to endpoint in ECG intervals for
duloxetine and placebo, respectively, were as follows: PR
(−3.3 ms, 1.0 ms, p<0.001), QRS (−0.3 ms, 0.4 ms,
p=0.32), QT (−5.3 ms, 1.7 ms, p<0.001), QTcB (4.8 ms,
1.9 ms, p=0.06), and QTcF (1.3 ms, 1.9 ms, p=0.26).
Chemistry and hematology
Rates of treatment-emergent PCS laboratory values were
low in all studies. In the short-term studies, there was a
significantly (p<0.05) higher incidence of alanine amino-
transferase (ALT) values >5 times upper limit of normal
(PCS criteria) among duloxetine-treated patients (0.6%)
compared with placebo-treated patients (0%). There were
no significant differences between duloxetine and placebo
in the rates of treatment-emergent PCS values for aspartate
aminotransferase, bilirubin, calcium, cholesterol, creatine
phosphokinase, creatinine, gamma-glutamyltransferase
(GGT), inorganic phosphorus, sodium, total protein, urea
nitrogen, or uric acid (all rates <1.2%). For those patients
enrolled for 6 months or more, treatment-emergent PCS
values occurred at a rate >1% only for high cholesterol
(1.6%, 11 of 706; PCS criteria = total cholesterol greater
than 7.76 mmol/L). In the 1-year study, two treatment-
emergent PCS values occurred at a rate >1%: high
cholesterol (2.1%) and high GGT (1.5%; PCS criteria for
GGT = greater than 135,000 U/L for women and greater
than 195,000 U/L for men).
There were no significant differences in the incidence of
hepatic-related treatment-emergent adverse events and
hepatic-related serious adverse events for duloxetine com-
pared with placebo in the short-term studies. No patients in
the short-term studies, 1-year study, or the sample that was
enrolled for 6 months or more met Hy’s rule (Hy’s rule is
defined as an ALT value greater than three times the upper
limit of normal together with a total bilirubin greater than
two times normal and reflects the presence of hepatocellular
injury) [39]. There was a significantly (p<0.05) higher
incidence of duloxetine-treated patients (0.6%) who dis-
continued due to a hepatic-related adverse event compared
with placebo-treated patients (0%). There was no evidence
Table 6 Vital signs and weight: treatment-emergent potentially clinically significant values
3–6-Month studies ≥6-Month exposure 1-Year study
Placebo
(N=535)
Duloxetine
(N=876)
Duloxetine
(N=721)
Duloxetine
(N=350)
Abnormality n/N (%) n/N (%) p
a (duloxetine
vs. placebo)
n/N (%) n/N (%)
Pulse High 1/527 (0.2) 4/855 (0.5) 0.308 1/721 (0.1) 2/347 (0.6)
Low 2/519 (0.4) 3/846 (0.4) 0.900 0/716 (0) 0/348 (0)
Sitting diastolic BP High 1/522 (0.2) 6/847 (0.7) 0.159 1/712 (0.1) 8/342 (2.3)
Low 3/523 (0.6) 3/852 (0.4) 0.607 2/718 (0.3) 3/346 (0.9)
Sitting systolic BP High 1/525 (0.2) 3/848 (0.4) 0.415 3/715 (0.4) 6/347 (1.7)
Low 3/517 (0.6) 2/845 (0.2) 0.525 1/708 (0.1) 11/340 (3.2)
Weight (kg) Gain 2/499 (0.4) 10/823 (1.2) 0.126 55/719 (7.6) 28/348 (8.0)
Loss 6/499 (1.2) 18/823 (2.2) 0.173 29/719 (4.0) 17/348 (4.9)
Criteria for PCS values: systolic low (≤90 and decrease from baseline ≥20), systolic high (≥180 and increase from baseline ≥20), diastolic low
(≤50 and decrease from baseline ≥15), diastolic high (≥105 and increase from baseline ≥15), pulse low (≤50 and decrease from baseline ≥15),
pulse high (≥120 and increase from baseline ≥15), weight low (decrease from baseline ≥10%), high (increase from baseline ≥10%)
N number of patients at risk of having potentially clinically significant (PCS) values at baseline, n number of patients with a PCS postbaseline
measurement
aCochran–Mantel–Haenszel test for general association, controlling for study
Clin Rheumatol (2009) 28:1035–1044 1041that longer-term treatment added to the risk of discontinu-
ation due to a hepatic-related adverse event: 0.6% of the
350 patients in the 1-year study discontinued due to a
hepatic-related adverse event.
Discussion
This comprehensive safety analysis revealed that the most
common TEAEs seen during duloxetine treatment of FM
were similar to those seen during duloxetine treatment of
other indications, including MDD, GAD, and DPNP. Most
TEAEs were mild to moderate in severity and were
transient. In the short-term 3- and 6-month studies, adverse
events leading to discontinuation varied, with no one event
responsible for more than 2% of patients discontinuing.
Overall, 19.5% discontinued due to an adverse event.
Duloxetine-treated patients had significantly larger
increases in BP and heart rates, compared with placebo-
treated patients, in short-term 3- and 6-month studies.
These increases, however, were not of clinical significance.
Furthermore, there was no evidence of higher rates of PCS
abnormal laboratory values, ECG parameters, vital signs, or
changes in body weight, for duloxetine-treated patients
compared with placebo-treated patients during 3–6-month
treatment, with one exception: A significantly higher
incidence of ALT values >5 times upper limit of normal
was found for duloxetine-treated patients (0.6%) compared
with placebo-treated patients (0%).
Over the course of 1-year open-label of treatment with
duloxetine, there was a somewhat higher total incidence of
certain adverse events and PCS values on laboratory
parameters. In the absence of a comparator, it seems most
likely that these increased rates were due to the longer
observation periodcompared with the 3-and6-month studies.
Overall, instances of PCS laboratory values were very low in
the sampleenrolled for 6 months orlonger, as well asinthe 1-
year study, with no discernable clinical pattern suggestive of a
specific body system or disease state.
While the overall pattern of adverse events during
duloxetine treatment was similar for the FM studies
compared with other disorders, the base rate of such
adverse events appears somewhat higher in FM. In the
treatment of MDD, for example, the incidence of common
adverse events has been reported to be generally lower for
both placebo and duloxetine than found here [40].
Although initial occurrences of adverse events tend to
occur early in treatment, the shorter duration (8–9 weeks) of
the MDD trials may account in part for this apparent
difference. Discontinuations due to adverse events occurred
in about 20% of patients in both the short-term 3- and 6-
month studies and the 1-year study. This rate is somewhat
higher than the discontinuation rate due to adverse events
of 11% reported in a review of 19 studies of short-term
treatment (duration, 8–26 weeks) of MDD with serotonin
reuptake inhibitors [41]. Rates of 9–10% for discontinua-
tion due to adverse events were found across six studies of
venlafaxine, a serotonin and norepinephrine reuptake
inhibitor of similar class to duloxetine, and four studies of
duloxetine, in the short-term treatment of MDD [42]. These
findings suggest that patients with FM report slightly more
adverse events and have somewhat higher rates of discon-
tinuation due to adverse events compared with other
disorders for which duloxetine has been studied, whether
on drug or placebo. Nevertheless, clinicians need to be
aware of the risk of discontinuation due to adverse events
with duloxetine in the treatment of fibromyalgia and balance
this risk against the likelihood of treatment response.
The cardiovascular safety of duloxetine has been
previously investigated across all conditions for which
duloxetine has been studied [43]. Using a database of 42
clinical trials, plus postmarketing safety studies, this recent
study found no evidence of cardiovascular risk [43].
Similarly, in the treatment of FM, no evidence of clinically
significant changes in ECG parameters or sustained
increases in BP was seen for duloxetine relative to placebo.
Although duloxetine’s noradrenergic effect suggests that it
is likely to cause increases in heart rate, only 0.5% of
patients in the 3- and 6-month studies, 0.1% of patients
enrolled for 6 months or more, and 0.6% of patients in the
1-year study had a clinically significant increase in pulse
rate. The QTc interval was prolonged to a clinically
meaningful degree in 0.4% of duloxetine-treated patients
compared with 0.3% of placebo-treated patients.
In the 3- and 6-month FM studies, small numbers of
patients lost or gained >10% in body weight. However,
among those duloxetine-treated patients who were en-
rolled for at least 6 months, 7.6% gained >10% in body
weight and 4.0% lost >10% in body weight. Similarly, in
the 1-year study, 8.0% gained >10% in body weight and
4.9% lost >10% in body weight. In the absence of a
placebo or other comparator, these changes over 6 months
and 1 year are difficult to interpret. A previous longer-
term (1 year) open-label study of duloxetine (80–120 mg/
day) for MDD found early (first few weeks) decreases in
mean body weight followed by a return to baseline and
then an increase on average of 1.1 kg by the end of the
study [44]. This pattern is consistent with what was found
here, with more patients losing >10% weight than gaining
>10% weight in the 3–6 months studies, but more patients
gaining >10% weight than losing >10% weight after being
enrolled for 6 months or more and in the 1-year study. The
overall mean change, however, was small (0.7 kg gain by
endpoint of the 1-year study).
1042 Clin Rheumatol (2009) 28:1035–1044The effect of duloxetine on ALT has been previously
found in other populations and is described in the product
labeling. Changes in ALT do not appear to predict
hepatotoxicity, and the absence of cases that met criteria
for Hy’s rule during either short- or long-term use supports
the conclusion that the risk of hepatotoxicity associated
with duloxetine in patients with FM is very low.
There has been considerable attention to the issue of
suicide risk with antidepressants [45, 46]. Because rates of
suicidality are typically very low, analysis of a pooled study
database is a particularly useful to test for any potential
drug-placebo difference. In the analyses of short-term
placebo-controlled studies of FM, there were no significant
differences between duloxetine and placebo in the inci-
dence of suicidal behavior or ideation according to adverse
event reporting. In the 1-year open-label study, four patients
were reported to have suicide-related behavior. However, in
the absence of a placebo control, these rates of suicide-
related behavior in the longer-term study are difficult to
interpret, particularly because elevated rates of suicide have
been found for individuals with widespread pain syndromes
like FM [47].
Strengths of this study include the large number of
patients treated with duloxetine in the shorter-term studies
(n=876). In addition, a broad range of safety assessments
were conducted. This report on the safety of duloxetine in
the treatment of fibromyalgia is limited by the fact that all
patients were participants in clinical trials with extensive
inclusion/exclusion criteria. In particular, patients with
certain comorbidities and patients on most other centrally
acting medications were excluded from the trials. In clinical
practice, psychiatric and medical comorbidity and poly-
pharmacy is common among patients with FM [48]. Thus,
the generalizability of the findings to typical clinical
practice patients who have psychiatric or medical comor-
bidities and who also receive concomitant medications is
not known.
Another limitation of this pooled safety analysis includes
the lack of a placebo group in the long-term safety study.
However, the fact that the safety findings from the longer-
term study are generally similar or show only slightly
increased rates of adverse events or laboratory/vital sign
values, relative to values from the 3- and 6-month studies,
may provide reassurance about longer-term use of dulox-
etine in fibromyalgia.
In conclusion, duloxetine in dosages from 20 to
120 mg/day demonstrated a similar safety and tolerability
p r o f i l ei nt h et r e a t m e n to fF Mt ot h a ts e e ni nt h et r e a t m e n t
of other indications. Most patients tolerate duloxetine
without clinically meaningful effects on vital signs,
cardiovascular parameters, or laboratory (chemistry, he-
matology) analytes.
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